Drug updated on 4/18/2024
| Dosage Form | Cream (topical; 0.005%) |
| Drug Class | Retinoids |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Summary
- Trifarotene (Aklief) is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older, targeting both facial and truncal acne.
- Two studies were analyzed to gather information on trifarotene's efficacy and safety profile.
- The studies highlight trifarotene's effectiveness in treating moderate acne on the face and trunk, particularly among adolescents aged 12 to 17. Success rates for treating facial acne are reported at 65.1%, and truncal acne at 66.9%.
- Both studies confirm trifarotene's good safety profile, noting side effects such as pruritus, irritation, and sunburn, which are in line with common adverse effects associated with retinoid use but are considered manageable.
- Although direct comparisons between trifarotene and other retinoids are not provided in the studies, they suggest that future research should include such comparisons, highlighting the convenience of its once-daily application and its effectiveness in treating both facial and truncal acne, even though cost may be a prohibitive factor.
- Subgroup analysis indicates that trifarotene could be particularly beneficial for adolescents aged 12 to 17, who are significantly affected by acne vulgaris and require comprehensive yet tolerable treatment options.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Aklief (trifarotene) Prescribing Information. | 2019 | Galderma Laboratories, L.P., Fort Worth, TX |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Advances in topical management of adolescent facial and truncal acne: a phase 3 pooled analysis of safety and efficacy of trifarotene 0.005% cream. | 2022 | Journal of Drugs in Dermatology |
| Trifarotene for the treatment of facial and truncal acne. | 2021 | The Annals of Pharmacotherapy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Guidelines of care for the management of acne vulgaris. | 2024 | Journal of the American Academy of Dermatology |